ERBB2 and gastric cancer: Food and Drug Administration (FDA) approved two new agents, the HER2-neu antagonist trastuzumab (in 2010) and the vascular endothelial growth factor (VEGF) antagonist ramucirumab (in 2014), for the treatment of advanced-stage GC (Bang et al., 2010; Fuchs et al., 2014).